Healthcare / Diagnostics & ResearchBSE
$22.07
-1.16 (-4.99%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 13%
FCF escenarios
weak_data · normalized FCF $-91.0M · quality 34.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
8/100
F
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$157M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-45.8%
↓Gross Margin
31.1%
↓Debt/Equity
6.72
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-41.3%
FCF CAGR
—
FCF margin
-463.6%
FCF / Net income
1.91x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $19.6M · net income $-47.7M · FCF $-91.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $19.6M | $19.6M | $97.2M | $62.8M | $96.9M |
| Net Income | $-47.7M | $-47.7M | $-23.2M | $-64.8M | $882070.00 |
| EBITDA | $-41.9M | $-41.9M | $13.9M | $-1.6M | $41.6M |
| EPS | -7.56 | -7.56 | -3.67 | -10.27 | 0.14 |
| Gross Margin | 31.1% | 31.1% | 92.3% | 84.2% | 92.1% |
| Operating Margin | -438.9% | -438.9% | -32.6% | -109.8% | 22.2% |
| Net Margin | -243.2% | -243.2% | -23.8% | -103.3% | 0.9% |
| Balance Sheet | |||||
| Debt/Equity | 6.72 | 6.72 | 4.01 | 3.26 | 1.87 |
| Current Ratio | 0.80 | 0.80 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-91.0M | $-91.0M | $-7.2M | $-293.2M | $-119.0M |
| Returns | |||||
| ROE | -45.8% | -45.8% | -15.2% | -37.0% | 0.4% |
| Valuation | |||||
| P/E | — | — | — | — | 857.14 |
| EV/EBITDA | — | — | 72.61 | — | 28.96 |
| P/B | 1.34 | 1.34 | 2.66 | 2.07 | 3.16 |
| Growth & Yield | |||||
| Revenue Growth | -79.8% | -79.8% | 54.9% | -35.2% | — |
| EPS Growth | -106.0% | -106.0% | 64.3% | -7435.7% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-11.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-3.67 → -7.56
Residual
-11.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.